Leadership & People

The ex-GSK supply head Ian McCubbin will join the independent UK organization aimed at advancing cell and gene therapies, but notes issues with scale and manufacturing ahead.

Sanofi India's managing director is moving on after an eventful innings that saw the company re-orient operations, moving out of certain non-strategic areas to focus on core therapies. Pre-pandemic early digital adoption appears to have played out well too for the French group’s listed Indian arm.

Nearly a year into the job, research chief Christian Rommel tells Scrip he is impressed with Bayer's arm's length approach to running acquired firms like AskBio and BlueRock and the task ahead is to deliver on the potential they offer, while getting later-stage projects across the approvals finishing line.

C-suite changes at Omega Therapeutics and promotions at Cabaletta Bio are among recent executive changes in the industry. Meanwhile, new directors were appointed at AN2 Therapeutics, among others.

Recent executive changes in the industry include the appointment of a new vice president of human resources at aTyr Pharma and promotions at Zhejiang Shapuaisi Pharmaceutical. Meanwhile, new directors were appointed at GlaxoSmithKline and Dicerna Pharmaceuticals, among others.

A new secretary appointed at Genor Biopharma and promotions at Zai Lab are among recent executive changes in the industry. Meanwhile, new directors were appointed at Tenaya Therapeutics, among others.

Rajkumar Kannan now leads Aerie, while other changes include former Genentech exec Saraswati Kenkare-Mitra joining Alector as head of R&D and Theresa LaVallee, formerly of Celldex Therapeutics, joining Coherus BioSciences as chief development officer.

C-Suite changes at Iterium Therapeutics and promotions at Exicure are among recent executive changes in the industry. Meanwhile, new board members were appointed at Biofrontera, among others.

C-Suite changes at AbCellera Biologics and promotions at Lyell Immunopharma are among recent executive moves in the industry. Meanwhile, new directors were appointed at Decibel Therapeutics, Curis and Ventus Therapeutics, among others.

CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.

C-suite changes at Relief Therapeutics and promotions at Black Diamond Therapeutics are among recent executive changes in the industry. Meanwhile, new directors were appointed at Adagio Therapeutics, OKYO Pharma and Tenaya Therapeutics, among others.

Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?